HC Wainwright & Co. Reiterates Buy on Zenas BioPharma, Maintains $44 Price Target

Benzinga Newsdesk www.benzinga.com Neutral 90.1%

Neg 0% Neu 90.1% Pos 0%

HC Wainwright & Co. analyst Matthew Caufield reiterates Zenas BioPharma (NASDAQ:ZBIO) with a Buy and maintains $44 price target.